Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab

[1]  M. Socinski,et al.  LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) , 2017 .

[2]  J. Ahn,et al.  Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors , 2017, Cancer Chemotherapy and Pharmacology.

[3]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[4]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[5]  J. Larkin,et al.  Management of toxicities of immune checkpoint inhibitors. , 2016, Cancer treatment reviews.

[6]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[8]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[10]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[11]  M. Binder,et al.  Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy , 2011, Medical oncology.

[12]  S. Steinberg,et al.  Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.

[13]  M. Greaves.  Anti-inflammatory action of corticosteroids. , 1976, Postgraduate medical journal.